Journal of Alcoholism & Drug Dependence
Open Access

Henry R Kranzler

Publications

• Research Article
  Variation in Mu-Opioid Receptor Gene (OPRM1) as a Moderator of Naltrexone Treatment to Reduce Heavy Drinking in a High Functioning Cohort
  Author(s): Andrew CH Chen, Jon Morgenstern, Christine M Davis, Alexis N Kuerbis, Jonathan Covault and Henry R Kranzler Andrew CH Chen, Jon Morgenstern, Christine M Davis, Alexis N Kuerbis, Jonathan Covault and Henry R Kranzler
  
  Background: It is well known that naltrexone, an FDA-approved medication for treatment of alcohol dependence, is effective for only a subset of individuals. Recent studies have examined the utility of a functional A118G single nucleotide polymorphism (SNP) of the mu-opioid receptor gene (OPRM1) as a predictor of naltrexone treatment response. Although the findings to date have generally been consistent with a moderating effect of the SNP, further evaluation of this hypothesis is warranted. Objective: To evaluate whether problem drinkers with one or two copies of the 118G allele respond better to naltrexone treatment. The treatment goal in this cohort of high functioning men who have sex with men (MSM) was to reduce heavy drinking, rather than to promote abstinence. Method: 112 subjects.. View More»
  DOI: 10.4172/2329-6488.1000101

  Abstract PDF

Relevant Topics